LP-PLA2 is now recognized as a positive biomarker for coronary heart disease (CHD), as its enzymatic activity generates pro-inflammatory and pro-oxidant metabolites [7,60,61,62]. This evidence concerns the gene PLA2G7 and coronary artery disorder.